Senior individuals are more susceptible to the irreversible outcomes of endothelial barrier dysfunction, the hallmark of Acute Respiratory Distress Syndrome (ARDS). The Severe Acute Respiratory Syndrome Coronovirus 2 (SARS-CoV-2) - inflicted ARDS delivers the devastating outcomes of the COVID-19 worldwide. Endothelial hyperpermeability has been associated with both the progression and establishment of the COVID-19 - related respiratory failure. In the present study we investigated the in vitro effects of Metformin in the permeability of bovine pulmonary artery endothelial cells. Our preliminary results suggest that moderate doses (0.1, 0.5, 1.0 mM) of this anti-diabetic agent enhance the vascular barrier integrity, since it produces an increase in the transendothelial resistance of endothelial monolayers. Thus, we speculate that Metformin may deliver a new therapeutic possibility in ARDS, alone or in combination with other barrier enhancers.

高龄人士更容易发生内皮屏障功能障碍的不可逆转结果，这是急性呼吸窘迫综合征（ARDS）的标志。严重急性呼吸系统综合症冠状病毒2（SARS-CoV-2）引起的ARDS在全球范围内带来了COVID-19的毁灭性后果。内皮通透性过高与COVID-19相关的呼吸衰竭的进展和确立有关。在本研究中，我们研究了二甲双胍对牛肺动脉内皮细胞通透性的体外作用。我们的初步结果表明，中等剂量的这种抗糖尿病药（0.1、0.5、1.0 mM）可以增强血管屏障的完整性，因为它会增加内皮细胞单层的跨内皮抵抗力。从而，